Estimating the cost of Rh testing and prophylaxis in early pregnancy: A time-driven activity-based costing study
- PMID: 38648923
- DOI: 10.1016/j.contraception.2024.110468
Estimating the cost of Rh testing and prophylaxis in early pregnancy: A time-driven activity-based costing study
Abstract
Objective: To estimate the cost of Rhesus (Rh) testing and prophylaxis for first-trimester vaginal bleeding in the ambulatory setting.
Study design: We used time-driven, activity-based costing to analyze tasks associated with Rh testing and prophylaxis of first-trimester vaginal bleeding at one hospital-based outpatient and two independent reproductive health clinics. At each site, we observed 10 patients undergoing Rh-typing and two patients undergoing Rh prophylaxis. We computed the costs of blood Rh-typing by both fingerstick and phlebotomy, cost of locating previous blood type in the electronic health record (available for 69.8% of hospital-based patients), and costs associated with Rh immune globulin prophylaxis. All costs are reported in 2021 US dollars.
Results: The hospital-based clinic reviewed the electronic health record to confirm Rh-status (cost, $26.18 per patient) and performed a phlebotomy, at $47.11 per patient, if none was recorded. The independent clinics typed blood by fingerstick, at a per-patient cost of $4.07. Rh-immune globulin administration costs, including the medication, were similar across facilities, at a mean of $145.66 per patient. Projected yearly costs for testing and prophylaxis were $55,831 for the hospital-based clinic, which was the lowest-volume site, $47,941 for Clinic A, which saw 150 patients/month, and $185,654 for Clinic B, which saw 600 patients/month.
Conclusions: Rh testing and prophylaxis for first-trimester vaginal bleeding generates considerable costs for outpatient facilities, even for Rh-positive patients with a prior blood type on record.
Implications: Rh testing and prophylaxis for first-trimester bleeding generate considerable costs even for Rh-positive patients and those with a previously known blood type. These findings highlight the need to reconsider this practice, which is no longer supported by evidence and already safely waived in multiple medical settings in the United States and around the world.
Keywords: Abortion; Blood type; Cost; Miscarriage; Pregnancy; Rh type.
Copyright © 2024 Elsevier Inc. All rights reserved.
Similar articles
-
Prevention of Rh alloimmunization.J Obstet Gynaecol Can. 2003 Sep;25(9):765-73. doi: 10.1016/s1701-2163(16)31006-4. J Obstet Gynaecol Can. 2003. PMID: 12970812
-
Economic analysis of foregoing Rh immunoglobulin for bleeding in pregnancy <12 weeks gestation.Contraception. 2024 Nov;139:110530. doi: 10.1016/j.contraception.2024.110530. Epub 2024 Jun 19. Contraception. 2024. PMID: 38906503
-
Rhesus D Immune Globulin in Early Pregnancy: A Clinical Review.Obstet Gynecol Clin North Am. 2025 Jun;52(2):207-218. doi: 10.1016/j.ogc.2024.12.012. Epub 2025 Feb 6. Obstet Gynecol Clin North Am. 2025. PMID: 40320266 Review.
-
Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.BJOG. 2016 Jul;123(8):1337-46. doi: 10.1111/1471-0528.13801. Epub 2015 Dec 10. BJOG. 2016. PMID: 26663771
-
Is Rh immune globulin needed in early first-trimester abortion? A review.Am J Obstet Gynecol. 2003 Mar;188(3):623-7. doi: 10.1067/mob.2003.208. Am J Obstet Gynecol. 2003. PMID: 12634631 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical